Neurocrine Biosciences Inc (NBIX)
Health Care ยท Biological Products, (No Diagnostic Substances)
Neurocrine Biosciences Inc (NBIX) is listed on Nasdaq, where its shares have traded since May 23, 1996. SentiSense covers Neurocrine Biosciences Inc in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Kyle Gano is its chief executive officer. The company reports 2,500 employees, and its corporate website is www.neurocrine.com.
About Neurocrine Biosciences Inc
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Latest reported results
Neurocrine Biosciences, Inc. reported revenue of $959.0 million for Q2 FY2026, up 39.5% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 760 institutions reported holding NBIX, with 100.5 million shares worth $16.9 billion in aggregate. The largest reported holders were BlackRock, Vanguard and JPMorgan Chase. Of the 5 largest reported holders, all 5 added shares during the quarter.
More on NBIX
- NBIX sentiment: whether news and social coverage of Neurocrine Biosciences Inc leans bullish or bearish, and the stories driving it.
- NBIX ownership: all 760 reporting institutions, plus insider and congressional trades.
- NBIX financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
Frequently asked questions
What does Neurocrine Biosciences Inc do?
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders.
What sector is NBIX in?
SentiSense classifies Neurocrine Biosciences Inc in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does NBIX stock trade?
Neurocrine Biosciences Inc (NBIX) is listed on Nasdaq, where its shares have traded since May 23, 1996.
Who is the CEO of Neurocrine Biosciences Inc?
Kyle Gano is the chief executive officer of Neurocrine Biosciences Inc.